Failure of etretinate in epidermodysplasia verruciformis.
In a patient suffering from benign lesions of epidermodysplasia verruciformis due to human papillomavirus type 5 little clinical improvement could be observed after 6 months of oral etretinate. The drug was given 75 mg/day for 1 month before dosage was reduced to 50 mg/day. Control biopsy after 3 months of treatment still revealed large quantities of virions and typical cytopathic effects in light and electron microscopic examination.
D000328:Adult; D004819:Epidermodysplasia Verruciformis / Q000188:drug therapy*; D005050:Etretinate / Q000627:therapeutic use*; D006801:Humans; D008297:Male
D005050:Etretinate